Search clinical trials for: grade 3B follicular lymphoma

Total 13673 results

Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Lymphoma, Large B-Cell, Diffuse | High-grade B-cell Lymphoma | Follicular Lymphoma Grade 3B | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
Marcela V. Maus, M.D.,Ph.D.

Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Incyte Corporation; Ipsen; BeiGene

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
ImmPACT Bio

Recruiting

Study of IMPT-314 in R/R Aggressive B-cell NHL

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
David Bond, MD

Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Genmab
AbbVie

Recruiting

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)

Diffuse Large B-Cell Lymphoma

France, Korea, Republic of, Spain, Belgium, Japan, Germany, Czechia, United Kingdom, Italy, Austria, United States, Poland
SWOG Cancer Research Network
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Follic Lymph to Diff Large B-Cell Lymphoma | Transformed Marg Zone Lymph to Diff...

United States
Patrick C. Johnson, MD
AstraZeneca

Recruiting

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Grade 3b Follicular Lymphoma | Refractory Aggressive B-cell Lymphomas | Aggressive B-cell NHL | De Novo or Transformed Indolent B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | T Cell/Histiocyte-rich Large B-cell Lymphoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
Washington University School of Medicine
Genentech, Inc.

Recruiting

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed B-Cell Lymphoma | Follicular Lymphoma Grade 3B

United States
University of Washington

Recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma

United States
Washington University School of Medicine
Genentech, Inc.

Recruiting

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | Aggressive Lymphoma | Follicular Lymphoma Grade 3

United States
Pell Bio-Med Technology Co., Ltd.

Recruiting

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
Fred Hutchinson Cancer Center
Nektar Therapeutics

Recruiting

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Grade 3b Follicular Lymphoma | Refractory Grade 3b Follicular... and other conditions

United States
Pell Bio-Med Technology Co., Ltd.

Recruiting

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
2seventy bio

Recruiting

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Diffuse Large B Cell Lymphoma (DLBCL)

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Not yet recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions

United States
oubai, MD/PhD

Recruiting

R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

Diffuse Large B Cell Lymphoma | Follicular Lymphoma Grade 3B

China
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
Genmab
AbbVie

Active, not recruiting

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

Diffuse Large B-cell Lymphoma

Korea, Republic of, Spain, Taiwan, Belgium, France, Israel, United Kingdom, China, United States, Netherlands, Japan, Sweden, Turkey, Australia, Singapore, Germany, Denmark, Poland, Italy, Hungary, Austria, Russian Federation, Norway, Canad... and more
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
Stanford University

Active, not recruiting

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

B-ALL | DLBCL | B-cell Non Hodgkin Lymphoma | Follicular Lymphoma Grade 3B

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Classic Hodgkin Lymphoma | Refractory... and other conditions

United States
Celgene

Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD)

Lymphoma, Non-Hodgkin

Italy, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland
University of Washington
Bayer

Terminated

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Non-Hodgkin's Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Grade 3b Follicular Lymphoma

United States
Genmab
AbbVie

Approved for marketing

Expanded Access Program for Epcoritamab

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-cell Lymphoma (HGBCL) | Grade 3B Follicular Lymphoma
University of Washington
National Cancer Institute (NCI)

Completed

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Grade 3b Follicular Lymphoma | Stage III Follicular Lymphoma | Composite Lymphoma | Stage I Diffuse Large B-Cell Lymphoma | Stage I Follicular Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage II Follicular Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma and other conditions

United States
Celgene

Completed

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse

United States
Seagen Inc.

Terminated

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma, Grade 3b | Lymphoma, B-cell | Lymphoma, Follicular, Grade 3b

United States
M.D. Anderson Cancer Center
Amgen

Terminated

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Lymphoma

United States
Seagen Inc.

Terminated

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Diffuse, Large B-Cell, Lymphoma | Follicular Lymphoma, Grade 3b | Transformed Lymphoma / DLBCL

United States, Puerto Rico
Ruijin Hospital

Unknown

R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B

Diffuse Large B-cell Lymphoma | Follicular Lymphoma Grade 3B

China
Azienda Ospedaliera Città della Salute e della...

Unknown

An Italian Experience on Grade 3b Follicular Lymphoma (FL3b-Oss-2015)

Grade 3b Follicular Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie
Hoffmann-La Roche

Completed

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular NHL Grade 3b

Hong Kong, Thailand, Sweden, Taiwan, Mexico, Austria, Serbia, China, Czech Republic, Australia, Malaysia, Croatia, Israel, South Africa, Bosnia and Herzegovina, Brazil, Bulgaria, Estonia, Latvia, Macedonia, The Former Yugoslav... and more
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (R-MEGACHOP)

Diffuse Large B-cell Lymphoma | Follicular Grade 3B Lymphoma

Spain
GlaxoSmithKline

Completed

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Lymphoma, Large-Cell, Diffuse
Celgene

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)

Lymphoma, Follicular

United States, Australia, Brazil, Canada, Chile, France, Germany, Italy, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Paolo Corradini
Annalisa Chiappella; Cristiana Carniti; Anna Dodero

Recruiting

Italian Observational Study on CAR-T Therapy for Lymphoma (CART-SIE)

Follicular Lymphoma | Mantle Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Low Grade B-Cell Lymphoma

Italy
Australasian Leukaemia and Lymphoma Group

Not yet recruiting

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | DLBCL, Nos Genetic Subtypes | High Grade B-Cell Lymphoma, Not Otherwise Specified | Follicular Large Cell Lymphoma, Relapsed | Follicular Large Cell Lymphoma
Sana Biotechnology

Recruiting

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma

United States
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Massachusetts General Hospital
Varian Medical Systems

Recruiting

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Lymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell Lymphoma

United States
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Australia
Reid Merryman, MD
AbbVie; Genmab

Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Follicular Lymphoma | Low Grade Non-Hodgkin's Lymphoma, Adult

United States

Search clinical trials for: grade 3B follicular lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations